Ligand Pharmaceuticals (LGND) Non-Current Debt (2011 - 2026)

Ligand Pharmaceuticals' (LGND) quarterly Non-Current Debt came in at $446.9 million in Q1 2026, little changed quarter-over-quarter from $446.2 million in Q4 2025.

Ligand Pharmaceuticals (LGND) Non-Current Debt (2011 - 2026) Analysis & Trends

Ligand Pharmaceuticals has disclosed Non-Current Debt across 7 years of filings, most recently posting $446.9 million for Q1 2026.

  • Non-Current Debt for Q1 2026 came in at $446.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $446.9 million (changed N/A YoY), and the FY2025 annual result was $446.2 million, changed N/A from the prior year.
  • Non-Current Debt came in at $446.9 million for Q1 2026 at Ligand Pharmaceuticals, roughly flat from $446.2 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $446.9 million in Q1 2026 to a low of $445.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 319.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Ligand Pharmaceuticals 5.47 Bn 4.69 Bn 48.45 Mn 446.90 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 446.90 Mn
Mar 31, 2026 446.90 Mn
Dec 31, 2025 446.19 Mn
Dec 31, 2025 446.19 Mn
Sep 30, 2025 445.49 Mn
Sep 30, 2025 445.49 Mn
Dec 31, 2015 205.37 Mn
Dec 31, 2015 205.37 Mn
Dec 31, 2014 195.91 Mn
Dec 31, 2014 195.91 Mn
Jun 30, 2013 1.97 Mn
Jun 30, 2013 1.97 Mn
Mar 31, 2013 5.49 Mn
Mar 31, 2013 5.49 Mn
Dec 31, 2012 13.44 Mn
Dec 31, 2012 13.44 Mn
Sep 30, 2012 17.88 Mn
Sep 30, 2012 17.88 Mn
Mar 31, 2012 26.44 Mn
Mar 31, 2012 26.44 Mn